Please provide your email address to receive an email when new articles are posted on . The integration of second-generation anti-vascular endothelial growth factor (VEGF) therapies into treatment ...

PORTLAND, Maine--(BUSINESS WIRE)--BerryDunn, a full-service accounting, tax, and consulting firm, will return for the 20 th year to the National Association of Medicaid Directors Fall Conference (NAMD ...

BerryDunn, a full-service accounting, tax, and consulting firm, will return for the 20th year to the National Association of Medicaid Directors Fall Conference (NAMD), taking place in National Harbor, ...

Kyowa Kirin Co ((KYKOF)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights ...

The study examined patients who were treated with intravitreal anti-vascular endothelial growth factor (anti-VEGF) compounds for their nAMD. A total of 76 patients (92 eyes) were followed for at least ...

Roche (RHHBY) announced new data from two studies on ophthalmology drug Vabysmo (faricimab). Vabysmo is already approved in several countries for people with neovascular or ‘wet’ age-related macular ...

Contivue platform with Susvimo received EU CE mark for neovascular AMD treatment, offering continuous ranibizumab delivery via an eye implant. Clinical studies, including Archway and LADDER, ...

The 40-week phase 2 clinical trial was a multicenter, chronic dosing trial for the evaluation of the safety and efficacy of subcutaneous MGB, “an investigational VEGF receptor tyrosine kinase ...

Company to present topline 40-week Phase 2 study efficacy and safety results of migaldendranib (MGB), a novel first-in-class nanomedicine for DME and nAMD Subcutaneous at-home administration ...

Microsoft is betting big on AI. Starting with integrating Bing with ChatGPT, it has implemented AI capabilities in its products. Microsoft Designer is a new product from Microsoft with AI capabilities ...

Neovascular age-related macular degeneration (nAMD) is a progressive eye disease characterized by choroidal neovascularization and subretinal hemorrhage and exudation, leading to vision impairment.